Surgical decision-making and prioritization for cancer patients at the onset of the COVID-19 pandemic: A multidisciplinary approach

Tzeng, Ching‐Wei D.; Cao, Hop S. Tran; Roland, Christina L.; Teshome, Mediget; Bednarski, Brian Keith; Ikoma, Naruhiko; Graham, Paul H.; Keung, Emily Z.; Scally, Christopher P.; Katz, Matthew H.G.; Gershenwald, Jeffrey E.; Lee, Jeffrey E.; Vauthey, Jean‐Nicolas

doi:10.1016/j.suronc.2020.04.029

Cited by 18 publications

(23 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We searched PubMed on April 05, 2021, using the search terms (“novel coronavirus” OR “SARS-CoV2” OR “COVID-19”) AND (“neuroendocrine tumors” OR “neuroendocrine tumours” OR “neuroendocrine neoplasms” OR “neuroendocrine carcinomas” OR “carcinoids”) for articles in English that documented the COVID-19 in patients with NENs. Sixteen articles appeared, including three case reports, 12 recommendations or consensus statements and one only mini-series of four cases among a large thoracic cancers series 19 , 22 , 23 , 24 17 , 18 , 20 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 .…”

Section: Introductionmentioning

confidence: 99%

Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study

Fazio

Halfdanarson

Salvia

et al. 2021

European Journal of Cancer

View full text Add to dashboard Cite

Background Specific data regarding COVID-19 in patients with neuroendocrine neoplasms (NEN) are lacking. This aim of this study is to describe the characteristics of NEN patients who tested SARS-CoV-2 positive. Material and methods This is a worldwide study collecting cases of NEN patients with a positive nasopharyngeal swab RT-PCR for SARS-CoV-2 between June 1, 2020, and March 31, 2021. Centers treating NEN patients were directly contacted by the principal investigator. Patients with NEN of any primary site, grade, and stage were included, excluding small-cell lung carcinoma and mixed adeno-neuroendocrine carcinoma. Results Among 81 centers directly contacted 88.8% responded and 48.6% of them declined due to lack of cases or interest. On March 31 st , 2021, eight recruiting centers enrolled 89 patients. Median age was 64 years at the COVID-19 diagnosis. Most patients had metastatic, non-functioning, low/intermediate grade gastro-entero-pancreatic (GEP) NEN, on treatment with somatostatin analogs (SSA) and radioligand therapy (RLT). Most of them had comorbidities. Only 8% of patients had high grade NEN and 12% were receiving chemotherapy. Most patients had symptoms or signs of COVID-19, mainly fever and cough. Only 3 patients underwent sub-intensive treatment, whereas the majority received medical therapies, mostly antibiotics. In two third of cases, no changes occurred for the anti-NEN therapy. More than 80% of patients completely recovered without sequelae whereas 7.8% patients died due to COVID-19. Conclusions Patients included in this study reflect the typical NEN population regardless of SARS-CoV-2. In the majority of cases they overcome COVID-19 without need of intensive care, short-term sequelae and discontinuation of systemic oncological therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study

Fazio

Halfdanarson

Salvia

et al. 2021

European Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…In our survey, this included all types of NET, independent of the primary location and histological grading. Although many NETs are relatively slow growing, a delay in curative surgical treatment may result in disease spreading and clearly has the potential to increase anxiety levels in these patients, thereby further negatively impacting their quality of life [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

Impact of the COVID-19 pandemic on neuroendocrine tumour services in England

et al. 2021

View full text Add to dashboard Cite

Purpose During the COVID-19 pandemic, there have been particular concerns regarding the related impact on specialist tumour services. Neuroendocrine tumour (NET) services are delivered in a highly specialised setting, typically delivered in a small number of centres that fulfil specific criteria as defined by the European Neuroendocrine Tumour Society (ENETS). We aimed to address the COVID-19-related impact on specialist NET tumour services in England and other countries. Methods Electronic survey addressing patient access and delivery of care distributed to all ENETS Centres of Excellence (CoE) in England and matching number of ENETS CoE elsewhere. Semi-quantitative and qualitative analyses of survey responses were performed. Results Survey response of ENETS CoE in England was 55% (6/11). Responses from six non-UK ENETS CoE elsewhere were received and analysed in a similar manner. Relevant disruption of various NET services was noted across all responding Centres, which included delayed patient appointments and investigations, reduced availability of treatment modalities including delayed surgical treatment and a major negative impact on research activities. The comparison between English and non-UK ENETS CoE suggested that the former had significantly greater concerns related to future research funding (p = 0.014), whilst having less disruption to multidisciplinary meetings (p = 0.01). A trend was also noted towards virtual patient appointments in ENETS CoE in England vs. elsewhere (p = 0.092). Conclusions Restoration of highly specialised NET services following COVID-19 and planning for future service delivery and research funding must take account of the severe challenges encountered during the pandemic.

show abstract

“…Still, it is necessary to consider that this group may be affected by the scarcity of essential medicines, and may suffer from the reduction of health activities, in the community, due to the implementation of the social distancing and lockdown guidelines ( 6 , 9 ). In some cases, patients may encounter difficulties in carrying out important procedures for their treatments, such as in the case of surgery, due to the high demand for hospitalization due to the pandemic ( 57 ), which may further increase the fear of the progression of the oncological disease ( 26 , 58 ). In addition, a systematic review recently demonstrated that during a pandemic, delay in surgery can reduce survival ( 59 ).…”

Section: The Impact Of Covid-19 In Cancer Patientsmentioning

confidence: 99%

The Sum of Fears in Cancer Patients Inside the Context of the COVID-19

et al. 2021

View full text Add to dashboard Cite

The pandemic resulting from COVID-19 has led to the collapse of the health system in dozens of countries. Parallel to clinical risk, the appearance or intensification of psychiatric symptoms has also been documented. The identification of groups at risk is essential for the establishment of preventive and therapeutic strategies. Cancer patients appear to be especially vulnerable both from a clinical and psychiatric perspective. Problems related to contamination and the cancer treatments themselves are intertwined, causing a sum of patients' fears to arise, which can cause mental effects. This study aims to review and investigate the impact of COVID-19 on the mental health of cancer patients and indicate possible support strategies.

show abstract

Surgical decision-making and prioritization for cancer patients at the onset of the COVID-19 pandemic: A multidisciplinary approach

Cited by 18 publications

References 3 publications

Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study

Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study

Impact of the COVID-19 pandemic on neuroendocrine tumour services in England

The Sum of Fears in Cancer Patients Inside the Context of the COVID-19

Contact Info

Product

Resources

About